• Product name
    Anti-PADI4 / PAD4 antibody
    See all PADI4 / PAD4 primary antibodies
  • Description
    Rabbit polyclonal to PADI4 / PAD4
  • Host species
  • Tested applications
    Suitable for: IP, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to amino acids 1-15 of human PADI4, conjugated to KLH via a C-terminal added cysteine residue

  • Positive control
    • Extracts of DMSO-treated HL60 cells.



Our Abpromise guarantee covers the use of ab50332 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent dilution. 2-4 µl of the antibody immunoprecipitatesPADI4 from DMSO-treated HL60 cells
WB 1/1000 - 1/2000. Predicted molecular weight: 74 kDa.


  • Function
    Catalyzes the citrullination/deimination of arginine residues of proteins. Citrullinates histone H3 at 'Arg-8' and/or 'Arg-17' and histone H4 at 'Arg-3', which prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.
  • Tissue specificity
    Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes.
  • Involvement in disease
    Genetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Note=Could have an important role in the pathogenesis of rheumatoid arthritis by increasing citrullination of proteins in rheumatoid arthritis synovial tissues, leading, in a cytokine-rich milieu, to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context.
  • Sequence similarities
    Belongs to the protein arginine deiminase family.
  • Cellular localization
    Cytoplasm. Nucleus. Cytoplasmic granule. Cytoplasmic granules of eosinophils and neutrophils.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC antibody
    • HL 60 PAD antibody
    • HL-60 PAD antibody
    • PAD 4 antibody
    • PAD antibody
    • PADI 4 antibody
    • PADI 5 antibody
    • PADI H protein antibody
    • Padi4 antibody
    • PADI4_HUMAN antibody
    • PADI5 antibody
    • PDI 4 antibody
    • PDI 5 antibody
    • PDI4 antibody
    • PDI5 antibody
    • Peptidyl arginine deiminase type IV antibody
    • Peptidyl arginine deiminase type V antibody
    • Peptidylarginine deiminase IV antibody
    • Protein arginine deiminase antibody
    • Protein arginine deiminase type 4 antibody
    • Protein arginine deiminase type IV antibody
    • Protein-arginine deiminase type IV antibody
    • Protein-arginine deiminase type-4 antibody
    see all


  • All lanes : Anti-PADI4 / PAD4 antibody (ab50332) at 1/1000 dilution

    Lane 1 : 293-T cells
    Lane 2 : 293-T cells transfected with PADI4 cDNA
    Lane 3 : HL60 cells
    Lane 4 : HL60 cells induced with 1.25% DMSO for three days

    All lanes : Goat Anti-Rabbit IgG

    Predicted band size: 74 kDa
    Observed band size: ~62 kDa
    why is the actual band size different from the predicted?


This product has been referenced in:
  • Kosgodage US  et al. Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme. Int J Mol Sci 20:N/A (2018). Read more (PubMed: 30597867) »
  • Lewis HD  et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol 11:189-91 (2015). Read more (PubMed: 25622091) »
See all 5 Publications for this product

Customer reviews and Q&As


Thank you for your enquiry. The exact protocols are as below: 1. DMSO was added to a concentration of 1.25% to normal HL60 media. This would be the equivalent to adding 125ul DMSO to 10ml media. No additional buffers were required. 2. The HL60 cells were normally at a 50% confluence at the point when the DMSO was added. 3. Cells were incubated, as normal, for another 3 days after the addition of 1.25% DMSO. I hope this information helps. If there is anything else that I can help you with, please do not hesitate to contact me.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up